<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946890</url>
  </required_header>
  <id_info>
    <org_study_id>BTP-66M12</org_study_id>
    <nct_id>NCT04946890</nct_id>
  </id_info>
  <brief_title>A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of MRX2843 Tablets in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Betta Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive oral MRX2843 for 28 days to study the side effects, tolerability and&#xD;
      best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is open-label, dose escalation study designed to characterize the safety, tolerability,&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered MRX2843 as a single&#xD;
      agent given daily for 28 days.&#xD;
&#xD;
      The study includes two parts, Phase I and Phase II, and is carried out in three phases. The&#xD;
      Phase I clinical study is divided into two phases: the dose escalation study (Ia) and the&#xD;
      expanded enrollment study (Ib). The third phase is the phase II research phase, which is&#xD;
      designed based on phase I clinical results.&#xD;
&#xD;
      Phase Ia：Cohorts of 3 patients receive MRX2843 until dose limiting toxicity is noted (DLT).&#xD;
      At that point cohorts will expand to 6 patients until MTD is determined.&#xD;
&#xD;
      Phase Ib/ II：According to the relevant data on safety and effectiveness, expand the&#xD;
      enrollment of FLT3 mutation relapsed/refractory AML patients at the appropriate dose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 Days</time_frame>
    <description>Safety: Incidence of dose limiting toxicity (DLT)and Adverse Event (AE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>28 Days</time_frame>
    <description>Explore the maximum tolerated dose (MTD) and phase II recommended dose (RP2D), and initially formulate a reasonable dosing plan;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>Maximum serum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to the time point of t (AUC0-tn)</measure>
    <time_frame>28 Days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to the time point of t (AUC0-tn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-inf)</measure>
    <time_frame>28 Days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>28 Days</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at equilibrium after oral administration（Vss/F）</measure>
    <time_frame>28 Days</time_frame>
    <description>Apparent volume of distribution at equilibrium after oral administration（Vss/F）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2z)</measure>
    <time_frame>28 Days</time_frame>
    <description>Plasma Decay Half-Life (t1/2z)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CLz/F)</measure>
    <time_frame>28 Days</time_frame>
    <description>Apparent Oral Clearance (CLz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma or serum concentration(Cav)</measure>
    <time_frame>28 Days</time_frame>
    <description>Average plasma or serum concentration(Cav)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in FLT3 mutation status in plasma</measure>
    <time_frame>28 Days</time_frame>
    <description>changes in FLT3 mutation status in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Remission (CR)</measure>
    <time_frame>28 Days</time_frame>
    <description>Rate of Complete Remission (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of partial remission (PR)</measure>
    <time_frame>28 Days</time_frame>
    <description>Rate of partial remission (PR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Acute Myeloid Leukemia Leukemia</condition>
  <arm_group>
    <arm_group_label>MRX2843 orally 80 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days&#xD;
1 to 21 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX2843 orally 120 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days&#xD;
1 to 21 of a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRX2843 orally 180 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days&#xD;
1 to 21 of a 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX2843</intervention_name>
    <description>MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively</description>
    <arm_group_label>MRX2843 orally 120 mg/d</arm_group_label>
    <arm_group_label>MRX2843 orally 180 mg/d</arm_group_label>
    <arm_group_label>MRX2843 orally 80 mg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females age ≥ 18 years;&#xD;
&#xD;
          2. Expected survival period ≥ 12 weeks;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          4. Histopathologically documented primary or secondary AML, as defined by WHO criteria,&#xD;
             confirmed by pathology review at treating institution, meeting at least one of the&#xD;
             following: i. After complete remission, leukemia cells reappear in peripheral blood,&#xD;
             or the ratio of bone marrow immature cells to bone marrow cells&gt; 5%, or leukemia cell&#xD;
             infiltration outside the bone marrow; ii. After standard protocol (including&#xD;
             cytarabine and a kind of Anthracycline or anthraquinone drugs) for refractory AML&#xD;
             patients who have not achieved complete remission after two courses of treatment;&#xD;
&#xD;
          5. During the dose escalation phase, there is no need to test for FLT3 mutation status;&#xD;
             for the expansion of the enrollment and phase II study phase, the FLT3 mutation status&#xD;
             test results within the past 6 months will be accepted; if not, the central laboratory&#xD;
             or research center needs to test and confirm the test Patients with FLT3 mutation&#xD;
             status in bone marrow or whole blood. The test results show that the subject has any&#xD;
             of the following FLT3 mutation types, and can be included in the group: FLT3 internal&#xD;
             tandem repeat (ITD), FLT3 tyrosine kinase domain (TKD);&#xD;
&#xD;
          6. Laboratory inspection must meet the following standards:&#xD;
&#xD;
               1. Blood routine: Under normal circumstances, the white blood cell count (WBC)&#xD;
                  ≤20×109/L; or the patient's white blood cell count (WBC)&gt;20×109/L before using&#xD;
                  hydroxyurea or cytarabine, use for a period of time and stop the drug After 3&#xD;
                  days, check the white blood cell count (WBC) ≤20×109/L;&#xD;
&#xD;
               2. Blood coagulation function: the international standardized ratio of prothrombin&#xD;
                  time and partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN);&#xD;
&#xD;
               3. Liver: If there is no clear liver metastasis, serum total bilirubin ≤1.5 ULN,&#xD;
                  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN; if&#xD;
                  there is clear Gilbert syndrome (Unconjugated hyperbilirubinemia), total&#xD;
                  bilirubin ≤ 3.0 ULN;&#xD;
&#xD;
               4. Kidney: Serum creatinine (Scr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min&#xD;
                  (calculated according to Cockcroft-Gault formula);&#xD;
&#xD;
          7. Normal or abnormal ocular retinal examination has no clinical significance;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received medications targeting MerTK and/or FLT3&#xD;
&#xD;
          2. Histologic diagnosis of acute promyelocytic leukemia;&#xD;
&#xD;
          3. Have had other malignant tumors in the past 5 years ;&#xD;
&#xD;
          4. Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or&#xD;
             higher;&#xD;
&#xD;
          5. The tumor involves the central nervous system and/or the testis;&#xD;
&#xD;
          6. Active, uncontrolled infection;&#xD;
&#xD;
          7. Radiation therapy within 4 weeks prior to study;&#xD;
&#xD;
          8. Received systemic glucocorticoids within 14 days before the first dose ；&#xD;
&#xD;
          9. Left ventricular ejection fraction ≤1 × ULN,or﹤50%. Clinically significant ECG QTc&#xD;
             prolongation (Male: &gt;450ms, Female: &gt;470ms).Significant cardiac disease；&#xD;
&#xD;
         10. Human immunodeficiency virus positivity;&#xD;
&#xD;
         11. Active hepatitis B or C or other active liver disease;&#xD;
&#xD;
         12. Women who are pregnant, lactating;&#xD;
&#xD;
         13. Have a history or family history of known or suspected retinitis pigmentosa;&#xD;
&#xD;
         14. Inability to swallow drugs orally, and conditions that seriously affect the absorption&#xD;
             or pharmacokinetic parameters of the test drug;&#xD;
&#xD;
         15. History of type 1 diabetes;&#xD;
&#xD;
         16. Any situation that is unstable or may endanger the safety of patients and their&#xD;
             compliance with research;&#xD;
&#xD;
         17. Medical condition, serious intercurrent illness, or other extenuating circumstance&#xD;
             that, in the judgment of the Principal Investigator, could jeopardize patient safety&#xD;
             or interfere with the objectives of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junmin Li, Ph.D</last_name>
    <phone>13817712211</phone>
    <email>Rjlijunmin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Junmin Li，Ph.D</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junmin Li, Ph.D</last_name>
      <phone>13817712211</phone>
      <email>Rjlijunmin@163.com</email>
    </contact>
    <investigator>
      <last_name>Junmin Li, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRX2843</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

